{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023510","form_type":"8-K","ticker":"SCYX","cik":"0001178253","company_name":"SCYNEXIS INC","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.836874+00:00","generated_at":"2026-06-22T00:42:47.037756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30","bullets":["Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.","BREXAFEMME net revenue $1.6M (up 23% QoQ); 5,785 total prescriptions written, up 13% vs Q2.","Cash, equivalents and short-term investments $96.1M; projected runway into Q2 2024.","CEO Marco Taglietti to retire Dec 31, 2022; David Angulo (CMO) to become CEO effective Jan 1, 2023.","PDUFA date Nov 30, 2022 for BREXAFEMME sNDA for prevention of recurrent VVC; company seeking commercialization partner."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023510","json":"https://secwatch.observer/filing/0000950170-22-023510.json","markdown":"https://secwatch.observer/filing/0000950170-22-023510.md","text":"https://secwatch.observer/filing/0000950170-22-023510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/0000950170-22-023510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/scyx-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:42:47.037756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d20b3ce56bf1648331892c532fc9aaa9fa2833f8","claim":"SCYNEXIS INC reported the third quarter ended September 30, 2022 results: revenue $1.6 million.","evidence_excerpt":"the Board effective January 1, 2023. • BREXAFEMME ® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022. • Coverage for BREXAFEMME increased to 130 million, or 70% of commercially insured lives, with the addition of a major national","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017022023510/0000950170-22-023510-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$1.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}